Certified Clinical Transplant Nurse (CCTN) Practice Exam

The introduction of Cyclosporine marked a significant advancement in immunosuppressive therapy for transplant patients, particularly in heart transplants. Prior to its use, transplant patients faced high rates of organ rejection due to the body's immune response to the implanted organ. Cyclosporine, as a potent immunosuppressant, effectively inhibited the T-cell response, which is essential for the rejection of transplanted organs.

This shift in immunosuppressive strategy led to dramatically improved outcomes, including increased rates of successful heart transplants. Patients were more likely to retain their transplanted hearts longer without serious rejection episodes, improving both short-term and long-term graft survival. This advancement laid the foundation for the broader application of heart transplants and enhanced the overall success of the procedure.

While the use of Cyclosporine contributed to better overall management of heart transplant patients, it did not eliminate surgical complications or reduce the need for donor organs. Anticoagulation needs are also influenced by numerous factors beyond immunosuppression. Thus, the increased rates of successful heart transplants stand out as a direct and critical impact of Cyclosporine's introduction in the field.